Background: In blood samples taken for testing purposes during drug infusion in the intensive care unit, there is a risk of interference due to drug-reactive interaction during the analysis.

Case Report: A 19-year-old female patient had undergone surgery for intracranial astrocytoma, 12 years ago. Acinetobacter baumannii was found in the blood culture and deep tracheal aspiration fluid of the patient who had a fever (39.2 °C) with a body temperature during the follow-up. The patient was started on colistin 2 * 4.5 million IU. After the colistin infusion, biochemical tests were requested to control the patient’s clinical situation. CK-MB mass and ProBNP values were measured in high concentrations. Cardiology consultation was requested to evaluate the increase in the CK-MB mass and ProBNP values. The patient's ECG and echocardiography showed no abnormality. The increase in cardiac markers was neither clinically acceptable nor insignificant. There was no hemolysis in the sample or analytical error in the device. Variability in the tests was thought to be due to the interference. As the bloodletting time was questioned, it was determined that it was taken during colistin treatment. In order to determine the effect of colistin-related interference on the other tests, the laboratory was contacted and additional tests (TSH, FT4, Anti- TPO, B-HCG, Estradiol, Prolactin, CA 125, CA 15-3, CA 19-9, Vitamin B12, C-Peptide, DDimer, PTH, 25 hydroxy vitamin D, PT, INR, APTT) were conducted. During colistin treatment, in many tests, bias was detected between -75 and + 268.80%.

Conclusion: Clinicians should consider suspicious test results that are incompatible with the diagnosis for the possibility of erroneous measurements due to colistin interference and review the sampling processes.

背景：在重症监护室中输注用于测试目的的血液样本中，由于分析期间的药物反应性相互作用，存在被干扰的风险。

病例报告：12年前，一名19岁的女性患者因颅内星形细胞瘤接受了手术。在随访期间发烧（39.2°C）且体温升高的患者的血液培养和气管深吸液中发现了鲍曼不动杆菌。该患者开始接受大肠菌素2 * 450万IU。大肠菌素输注后，要求进行生化检查以控制患者的临床情况。在高浓度下测量CK-MB质量和ProBNP值。要求进行心脏病学咨询以评估CK-MB质量和ProBNP值的增加。患者的心电图和超声心动图检查未见异常。心脏标志物的增加既不是临床上可接受的，也不是微不足道的。样品中没有溶血或装置中的分析错误。测试的差异被认为是由于干扰引起的。由于质疑放血时间，因此确定是在粘菌素治疗期间服用的。为了确定大肠菌素相关干扰对其他检测的影响，请与实验室联系并进行其他检测（TSH，FT4，抗TPO，B-HCG，雌二醇，催乳素，CA 125，CA 15-3，CA 19 -9，进行维生素B12，C-肽，DDimer，PTH，25羟基维生素D，PT，INR，APTT）。在粘菌素治疗期间，在许多测试中，检测到的偏倚在-75至+ 268.80％之间。进行抗-TPO，B-HCG，雌二醇，催乳素，CA 125，CA 15-3，CA 19-9，维生素B12，C-肽，DDimer，PTH，25羟基维生素D，PT，INR，APTT）。在粘菌素治疗期间，在许多测试中，检测到的偏倚在-75至+ 268.80％之间。进行了抗TPO，B-HCG，雌二醇，催乳素，CA 125，CA 15-3，CA 19-9，维生素B12，C肽，DDimer，PTH，25羟基维生素D，PT，INR，APTT）。在粘菌素治疗期间，在许多测试中，检测到的偏倚在-75至+ 268.80％之间。

结论：临床医生应考虑与诊断不符的可疑测试结果，以免由于大肠菌素干扰而导致错误测量，并复查采样过程。